Inflammatory Biomarkers in Disease Prognosis
Inflammatory Biomarkers in Disease Prognosis is a research topic within Oncology. Science Explorer counts 27k research works in it since 1951. 19.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the intricate relationship between inflammation and cancer, focusing on the role of immunity, systemic inflammatory response, platelets, and various prognostic markers in cancer development, progression, and treatment effectiveness. It delves into the mechanisms of inflammation-induced cancer, the impact of platelets on metastasis, and the potential of inflammatory pathways as therapeutic targets.
- Inflammation
- Cancer
- Immunity
- Neutrophil-to-Lymphocyte Ratio
- Platelets
- Tumor Microenvironment
- Systemic Inflammatory Response
- Metastasis
- Thrombosis
- Prognostic Markers
- Research works
- 27k fractional, since 1951
- In the world top 10%
- 5.1k per year above
- Top-10% rate
- 19.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +88% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Inflammatory Biomarkers in Disease Prognosis research?
By volume, China and Türkiye publish the most (3.6k and 773 works in 2022–2025).
By volume, 2022–2025
- 1 China 3.6k works
- 2 Türkiye 773 works
- 3 United States 730 works
- 4 Japan 525 works
- 5 India 334 works
- 6 Indonesia 298 works
- 7 Italy 211 works
- 8 South Korea 196 works
- 9 United Kingdom 161 works
- 10 Iran 151 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Inflammatory Biomarkers in Disease Prognosis research?
By volume in 2022–2025, Sağlık Bilimleri Üniversitesi publishes the most Inflammatory Biomarkers in Disease Prognosis research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sichuan University.
By volume, 2022–2025
- 1 Sağlık Bilimleri ÜniversitesiTürkiye 78 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 65 works
- 3 Sichuan UniversityChina 62 works
- 4 Capital Medical UniversityChina 57 works
- 5 Sun Yat-sen UniversityChina 56 works
- 6 Fujian Medical UniversityChina 53 works
- 7 Nanjing Medical UniversityChina 47 works
- 8 West China Hospital of Sichuan UniversityChina 42 works
- 9 Wenzhou Medical UniversityChina 40 works
- 10 Chongqing Medical UniversityChina 36 works
Who are the leading researchers in Inflammatory Biomarkers in Disease Prognosis?
The most-cited researchers publishing on Inflammatory Biomarkers in Disease Prognosis include Alberto Mantovani.
- 1 Alberto Mantovani Italy 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Inflammatory Biomarkers in Disease Prognosis research done?
The largest centres of Inflammatory Biomarkers in Disease Prognosis research in 2022–2025 are Beijing (China), Guangzhou (China), Shanghai (China) and Istanbul (Türkiye).
Where is the best place to study Inflammatory Biomarkers in Disease Prognosis?
Among universities, judged by research, Fujian Medical University, Nanjing Medical University and Wenzhou Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Fujian Medical UniversityChina | 73.0 | 27.2% | 17.5× | 53 | +263.4% |
| 2 | Nanjing Medical UniversityChina | 71.3 | 30.8% | 10.8× | 47 | +155.0% |
| 3 | Wenzhou Medical UniversityChina | 71.0 | 28.0% | 13.4× | 40 | +339.4% |
| 4 | Capital Medical UniversityChina | 68.7 | 26.6% | 11.5× | 57 | +125.0% |
| 5 | Anhui Medical UniversityChina | 68.0 | 27.0% | 12.8× | 32 | +190.8% |
| 6 | Guangxi Medical UniversityChina | 67.7 | 26.1% | 21.6× | 32 | +424.3% |
| 7 | Xuzhou Medical CollegeChina | 67.6 | 25.6% | 17.9× | 32 | +288.9% |
| 8 | Shanxi Medical UniversityChina | 66.8 | 30.3% | 11.7× | 22 | +223.8% |
| 9 | Dalian Medical UniversityChina | 66.5 | 36.9% | 11.2× | 18 | +157.4% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 64.7 | 26.1% | 7.8× | 65 | +134.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Inflammatory Biomarkers in Disease Prognosis research growing?
Output in 2018–2022 was 88% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Inflammatory Biomarkers in Disease Prognosis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.